|
US5458878A
(en)
*
|
1990-01-02 |
1995-10-17 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity
|
|
IL116436A
(en)
|
1995-12-18 |
2006-12-31 |
Yissum Res Dev Co |
Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND
|
|
IL118570A
(en)
*
|
1996-06-04 |
2007-06-17 |
Shai Yarkoni |
Use of a chimeric protein that includes Met – GnRH in the preparation of a pharmaceutical preparation for the treatment of adenocarcinoma or patocarcinoma
|
|
CA2271291A1
(en)
|
1996-11-06 |
1998-05-14 |
The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services |
Protease-activatable pseudomonas exotoxin a-like proproteins
|
|
AU5166698A
(en)
*
|
1996-11-08 |
1998-05-29 |
Emory University |
Method for treating certain pediatric acute leukemias
|
|
US7314632B1
(en)
*
|
1997-07-11 |
2008-01-01 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pseudomonas exotoxin A-like chimeric immunogens
|
|
EP1000163B1
(de)
*
|
1997-07-11 |
2005-10-19 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of Health and Human Services |
Pseudomonas exotoxin-a-ähnliche chimerische immunogene
|
|
US20030054012A1
(en)
*
|
2000-05-12 |
2003-03-20 |
Fitzgerald David J. |
Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
|
|
US6645490B2
(en)
*
|
1998-03-02 |
2003-11-11 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
|
|
US7157418B1
(en)
|
1998-07-22 |
2007-01-02 |
Osprey Pharmaceuticals, Ltd. |
Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
|
|
US7223397B1
(en)
*
|
1999-01-07 |
2007-05-29 |
Research Development Foundation |
Potentiation of anti-CD38-Immunotoxin cytotoxicity
|
|
DE60137969D1
(de)
*
|
2000-12-21 |
2009-04-23 |
Us Gov Health & Human Serv |
Ein chimäres protein das nichttoxische pseudomonas exotoxin a und typ iv pilin sequenzen enthält
|
|
DE60236450D1
(de)
|
2001-09-26 |
2010-07-01 |
Us Health |
Mutierte anti-cd22-antikörper mit erhöhter affinität zu cd22-exprimierenden leukämiezellen
|
|
US20070196366A1
(en)
|
2003-04-30 |
2007-08-23 |
Uwe Zangemeister-Wittke |
Methods for treating cancer using an immunotoxin
|
|
ES2343965T3
(es)
|
2003-11-25 |
2010-08-13 |
The Government Of The United States, As Represented By The Secretary Of Health And Human Services |
Anticuerpos anti-cd22 e inmunocongujados mutados.
|
|
US7713737B2
(en)
*
|
2004-10-04 |
2010-05-11 |
Trinity Biosystems, Inc. |
Methods and compositions for needleless delivery of macromolecules
|
|
US7611714B2
(en)
|
2004-10-04 |
2009-11-03 |
Trinity Biosystems, Inc. |
Methods and compositions for immunizing against Pseudomonas infection
|
|
WO2006125076A2
(en)
|
2005-05-18 |
2006-11-23 |
Trinity Biosystems, Inc. |
Methods and compositions for immunizing against chlamydia infection
|
|
CA2941466C
(en)
|
2005-07-29 |
2019-12-03 |
The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services |
Mutated pseudomonas exotoxins with reduced antigenicity
|
|
WO2007067597A2
(en)
*
|
2005-12-05 |
2007-06-14 |
Trinity Biosystems, Inc. |
Methods and compositions for needleless delivery of binding partners
|
|
EP1966246A4
(de)
*
|
2005-12-05 |
2010-01-06 |
Trinity Biosystems Inc |
Verfahren und zusammensetzungen zur nadellosen verabreichung von antikörpern
|
|
WO2007109110A2
(en)
|
2006-03-16 |
2007-09-27 |
Trinity Biosystems, Inc. |
Methods for increasing the size of animals using needleless delivery constructs
|
|
EP2046375B1
(de)
|
2006-07-20 |
2017-04-05 |
The General Hospital Corporation |
Verfahren und zusammensetzungen zur selektiven aktivierung von protoxinen durch kombinatorisches targeting
|
|
US20090092660A1
(en)
*
|
2006-08-09 |
2009-04-09 |
Trinity Biosystems, Inc. |
Methods and compositions for needleless delivery of particles
|
|
JP2010534061A
(ja)
*
|
2007-07-20 |
2010-11-04 |
ザ ジェネラル ホスピタル コーポレイション |
組換えコレラ菌外毒素
|
|
CA2698357C
(en)
|
2007-09-04 |
2017-06-06 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity
|
|
WO2010045495A2
(en)
|
2008-10-16 |
2010-04-22 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
|
|
WO2011031441A1
(en)
|
2009-08-28 |
2011-03-17 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Therapy with a chimeric molecule and a pro-apoptotic agent
|
|
AU2010292069B2
(en)
|
2009-09-11 |
2015-08-13 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Improved Pseudomonas Exotoxin A with reduced immunogenicity
|
|
WO2011100455A1
(en)
|
2010-02-12 |
2011-08-18 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Inhibition of antibody responses to foreign proteins
|
|
CN104689314B
(zh)
|
2010-06-16 |
2018-02-02 |
高等教育联邦系统-匹兹堡大学 |
内质蛋白的抗体及其用途
|
|
SG10201506030RA
(en)
|
2010-07-30 |
2015-09-29 |
Medimmune Llc |
Method for purifying active polypeptides or immunoconjugates
|
|
US11246915B2
(en)
|
2010-09-15 |
2022-02-15 |
Applied Molecular Transport Inc. |
Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
|
|
WO2012036746A1
(en)
|
2010-09-15 |
2012-03-22 |
Randall J Mrsny |
Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
|
|
WO2012145469A1
(en)
|
2011-04-19 |
2012-10-26 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human monoclonal antibodies specific for glypican-3 and use thereof
|
|
ES2635416T3
(es)
|
2011-06-09 |
2017-10-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Exotoxina A de pseudomonas con epítopos de linfocitos T y/o linfocitos B menos inmunogénicos
|
|
US8932586B2
(en)
|
2011-09-06 |
2015-01-13 |
Intrexon Corporation |
Modified forms of Pseudomonas exotoxin A
|
|
WO2013039916A1
(en)
|
2011-09-12 |
2013-03-21 |
The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services |
Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
|
|
EP2755993B1
(de)
|
2011-09-16 |
2017-11-08 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Pseudomonas exotoxin a mit weniger immunogenen b-zellepitopen
|
|
EP2764025B1
(de)
|
2011-10-04 |
2017-11-29 |
IGEM Therapeutics Limited |
Ige-antikörper gegen hmw-maa
|
|
US9409994B2
(en)
|
2012-06-01 |
2016-08-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High-affinity monoclonal antibodies to glypican-3 and use thereof
|
|
US9409992B2
(en)
|
2012-08-21 |
2016-08-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin domain-specific monoclonal antibodies and use thereof
|
|
EP2900695B1
(de)
|
2012-09-27 |
2018-01-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin-antikörper und verfahren zur auslösung einer starken antitumoraktivität
|
|
EP3494992B1
(de)
|
2012-12-20 |
2022-07-27 |
Medimmune Limited |
Rückfaltung und reinigung von moxetumomab pasudotox
|
|
WO2014160627A1
(en)
|
2013-03-25 |
2014-10-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
|
|
WO2015054691A2
(en)
|
2013-10-11 |
2015-04-16 |
The United States Of America, As Pepresented By The Secretary, Department Of Health And Human Services |
Tem8 antibodies and their use
|
|
EP3066118B1
(de)
|
2013-11-06 |
2020-01-08 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Alk-antikörper, konjugate und chimäre antigenrezeptoren und deren verwendung
|
|
US10421958B2
(en)
|
2014-02-05 |
2019-09-24 |
Molecular Templates, Inc. |
Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
|
|
RU2723178C2
(ru)
|
2014-05-07 |
2020-06-09 |
ЭППЛАЙД МОЛЕКЬЮЛАР ТРАНСПОРТ ЭлЭлСи |
Слитые молекулы, происходящие от Cholix-токсина, для пероральной доставки биологически активных нагрузок
|
|
EP3473271B1
(de)
|
2014-07-31 |
2022-07-20 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Humane monoklonale antikörper gegen epha4 und deren verwendung
|
|
US10604582B2
(en)
|
2014-09-17 |
2020-03-31 |
The United States Of America, As Represented By The Secretary, Department Of Health |
Anti-CD276 antibodies (B7H3)
|
|
US10676723B2
(en)
|
2015-05-11 |
2020-06-09 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
WO2017049296A1
(en)
|
2015-09-20 |
2017-03-23 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
|
|
KR102776145B1
(ko)
*
|
2015-11-13 |
2025-03-04 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
항-bcma 폴리펩티드 및 단백질
|
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
|
AU2017305170A1
(en)
|
2016-08-02 |
2019-02-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
|
|
WO2018035046A1
(en)
|
2016-08-15 |
2018-02-22 |
President And Fellows Of Harvard College |
Treating infections using idsd from proteus mirabilis
|
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
AU2017382883B2
(en)
|
2016-12-21 |
2024-07-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for FLT3 and uses thereof
|
|
US11390683B2
(en)
|
2017-05-18 |
2022-07-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin polypeptides and proteins
|
|
AU2018268970B2
(en)
|
2017-05-19 |
2024-12-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
|
|
WO2019006280A1
(en)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
|
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
|
|
WO2019055955A1
(en)
|
2017-09-18 |
2019-03-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
IMMUNOTOXINS WITH ALBUMIN BINDING DOMAIN
|
|
HUE059330T2
(hu)
|
2018-03-08 |
2022-11-28 |
Applied Molecular Transport Inc |
Toxinból származó bejuttatási konstrukciók orális beadásra
|
|
JP7459043B2
(ja)
|
2018-07-12 |
2024-04-01 |
ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
親和性成熟ｃｄ２２特異的モノクローナル抗体およびその使用
|
|
US12012463B2
(en)
|
2018-08-08 |
2024-06-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-2 and uses thereof
|
|
JP7487193B2
(ja)
|
2018-11-07 |
2024-05-20 |
アプライド モレキュラー トランスポート インコーポレイテッド |
異種ペイロードの経口送達のためのコリックス由来担体
|
|
AU2020206308A1
(en)
|
2019-01-08 |
2021-07-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross-species single domain antibodies targeting mesothelin for treating solid tumors
|
|
WO2020154150A1
(en)
|
2019-01-22 |
2020-07-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-1 and methods of use
|
|
CA3142833A1
(en)
|
2019-07-02 |
2021-01-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind egfrviii and their use
|
|
KR20220066056A
(ko)
|
2019-08-16 |
2022-05-23 |
어플라이드 몰레큘라 트랜스포트 인크. |
조성물, 제형, 및 인터루킨 제조 및 정제
|
|
CN119899265A
(zh)
|
2019-10-22 |
2025-04-29 |
美国政府(由卫生和人类服务部的部长所代表) |
用于治疗多种实体瘤的靶向b7h3（cd276）的高亲和力纳米抗体
|
|
WO2021097289A1
(en)
|
2019-11-15 |
2021-05-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Pegylated recombinant immunotoxins
|
|
EP4110823A1
(de)
|
2020-02-26 |
2023-01-04 |
A2 Biotherapeutics, Inc. |
Gegen mage-a3-peptid-mhc-komplexe gerichtete polypeptide und verfahren zu deren verwendung
|
|
WO2022093745A1
(en)
|
2020-10-26 |
2022-05-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
|
TW202231663A
(zh)
|
2020-12-22 |
2022-08-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
抗ｉｌ－４ｒ抗體或其抗原結合片段的複合物及醫藥用途
|
|
US20240218055A1
(en)
|
2021-04-29 |
2024-07-04 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
|
AU2022291120A1
(en)
|
2021-06-09 |
2023-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross species single domain antibodies targeting pd-l1 for treating solid tumors
|
|
WO2023076881A1
(en)
|
2021-10-26 |
2023-05-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
|
|
EP4448566A1
(de)
|
2021-12-17 |
2024-10-23 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Anti-mesothelin-polypeptide, proteine und chimäre antigenrezeptoren
|
|
WO2024050399A1
(en)
|
2022-09-01 |
2024-03-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
|
|
WO2024104584A1
(en)
|
2022-11-17 |
2024-05-23 |
University Of Cape Town |
Deimmunized pseudomonas exotoxin a
|
|
WO2024238346A1
(en)
|
2023-05-12 |
2024-11-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies that specifically bind the s2 subunit of sars-cov-2 spike protein and compositions and uses thereof
|
|
WO2025014896A1
(en)
|
2023-07-07 |
2025-01-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Humanized 40h3 antibody
|
|
WO2025019228A1
(en)
|
2023-07-20 |
2025-01-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
|
|
WO2025106427A1
(en)
|
2023-11-14 |
2025-05-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
|
|
WO2025171238A1
(en)
|
2024-02-07 |
2025-08-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof
|